Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2021 | Updates from EMBT 2021: HSCT, CAR-T and COVID-19

Christian Chabannon • 12 Mar 2021

EBMT 2021

General CAR-T

Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, outlines the most exciting updates being presented at EBMT 2021, highlighting developments in the field of hematopoietic stem cell transplantation (HSCT), chimeric antigen receptor T-cell (CAR-T) therapy and the impacts of the COVID-19 pandemic on the management of patients receiving transplantation or CAR-T therapy. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Prof. Christian Chabannon, MD, PhD, has participated in consultancy work or speakers bureaus for Kite/Gilead, Novartis, BMS/Celgene, Janssen, Bellicum Pharmaceuticals, BlueBirdBio, Sanofi SA and Terumo BCT.

The consequences of regulatory changes on access to devices and reagents needed for graft processing

Christian Chabannon • 16 Apr 2024

Improving access to advanced therapies: the access to CAR-T in Europe

Christian Chabannon • 17 Feb 2024

Addressing the changing needs for ad-hoc resources for safe delivery of advanced therapies

Christian Chabannon • 17 Feb 2024

IFM-2015-03: plerixafor before salvage ASCT in R/R myeloma

Christian Chabannon • 21 Oct 2023

Related Videos

Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD

Florent Malard • 11 Apr 2024

Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD

Mohamad Mohty • 17 Apr 2024

HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors

Rémy Duléry • 15 Apr 2024

The consequences of regulatory changes on access to devices and reagents needed for graft processing

Christian Chabannon • 16 Apr 2024